Jun 2026 (Q2 FY26) — Jul 29, 2026
CONMED Q2 FY26 — Strong Organic Growth and Strategic Progress Amidst Refinancing
Read the full callCONMED (CNMD) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CONMED earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 343 | +0.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 10.6 | −0.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 23.1 | +7.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$46.05 −1.43% · −$0.67
Performance +1.9% 1Y
1Y: $45.19 on 17 Oct 2025 → $46.05. High $51.86 (3 Aug 2026), low $32.11 (17 Jun 2026).
- Previous close
- $46.72
- 52-week range
- $32.11 – $51.86
- One year
- −3.62%
Overview
- Symbol
- CNMD
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CONMED earnings calls (CNMD)
Financials
What the filings say
Net profit, year on year: +8% (quarter to jun 2026 against jun 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 332 | 317 | 346 | 321 | 342 | 338 | 373 | 343 |
| Operating profit | 47 | 66 | 52 | 16 | 38 | 12 | 37 | 36 |
| Operating margin | 14.2% | 20.8% | 15.2% | 5.0% | 11.2% | 3.5% | 9.8% | 10.6% |
| Interest | 10 | 9 | 9 | 8 | 8 | 8 | 7 | 8 |
| Profit before tax | 38 | 56 | 44 | 8 | 30 | 4 | 29 | 31 |
| Tax rate | 20.1% | 13.2% | 22.7% | 21.3% | 28.4% | 33.1% | 42.8% | 26.4% |
| Net profit | 30 | 49 | 34 | 6 | 21 | 3 | 17 | 23 |
| EPS ($ per share) | 0.97 | 1.59 | — | 0.19 | 0.69 | 0.09 | — | 0.77 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 465 | 471 | 457 | 497 | 413 | 453 | 560 | 589 |
| Total liabilities | 707 | 1,065 | 1,043 | 981 | 1,552 | 1,466 | 1,344 | 1,293 |
| Fixed assets | 113 | 119 | 111 | 109 | 116 | 121 | 116 | 113 |
| Total assets | 1,369 | 1,775 | 1,752 | 1,766 | 2,298 | 2,300 | 2,306 | 2,326 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 75 | 95 | 65 | 112 | 33 | 125 | 167 | 171 |
| Cash from investing | -17 | -388 | -14 | -15 | -250 | -20 | -13 | -21 |
| Cash from financing | -72 | 301 | -52 | -102 | 225 | -110 | -151 | -136 |
| Net cash flow | -15 | 8 | 2 | -7 | 8 | -5 | 0 | 16 |
| Capital expenditure | -17 | -20 | -13 | -15 | -22 | -19 | -13 | -20 |
| Free cash flow | 58 | 75 | 52 | 97 | 12 | 106 | 154 | 151 |
Insider filings
17 filings between Oct 31, 2025 and Sep 8, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$161.1K
2 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Option exercise — converted options into shares
- 4
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Garner Todd W | — | $150.5K | Nov 6, 2025 |
| Glaze Richard | — | $10.6K | Nov 21, 2025 |
Latest filings (42)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 8, 2026 | Kelderman Kim Director | Option exercise | 500 | $0 |
| Jun 2, 2026 | Schwarzentraub Barbara J Director | Option exercise | 668 | $0 |
| Jun 2, 2026 | Council LaVerne H Director | Option exercise | 668 | $0 |
| Jun 2, 2026 | Bronson David M. Director | Option exercise | 668 | $0 |
| Jun 2, 2026 | Farkas Charles Director | Option exercise | 668 | $0 |
| Jun 2, 2026 | Kaye Mark Director | Option exercise | 668 | $0 |
| Mar 6, 2026 | Lalomia Brent Executive VP RA, QA | Tax withheld | 26 | $1.0K |
| Mar 6, 2026 | Lalomia Brent Executive VP RA, QA | Option exercise | 75 | $0 |
| Feb 24, 2026 | Kaye Mark Director | Option exercise | 152 | $0 |
| Nov 21, 2025 | Glaze Richard Chief Information Officer | Sale 10b5-1 plan | 257 | $10.6K |
| Nov 20, 2025 | Glaze Richard Chief Information Officer | Tax withheld | 118 | $4.8K |
| Nov 20, 2025 | Glaze Richard Chief Information Officer | Option exercise | 375 | $0 |
| Nov 6, 2025 | Garner Todd W Executive Vice President & CFO | Sale 10b5-1 plan | 3,500 | $150.5K |
| Nov 4, 2025 | Foust Hollie K General Counsel & Corp Sec | Tax withheld | 1,114 | $50.9K |
| Nov 4, 2025 | Foust Hollie K General Counsel & Corp Sec | Option exercise | 4,000 | $0 |
| Oct 31, 2025 | Garner Todd W Executive Vice President & CFO | Option exercise | 7,500 | $0 |
| Oct 31, 2025 | Garner Todd W Executive Vice President & CFO | Tax withheld | 2,164 | $95.2K |
| Sep 12, 2025 | Farkas Charles Director | Sale | 1,103 | $59.0K |
| Sep 12, 2025 | Farkas Charles Director | Sale | 897 | $48.0K |
| Aug 7, 2025 | Garner Todd W Executive Vice President & CFO | Sale | 598 | $31.4K |
| Jun 3, 2025 | Council LaVerne H Director | Option exercise | 479 | $0 |
| Jun 3, 2025 | Aronson Martha Goldberg Director | Option exercise | 479 | $0 |
| Jun 3, 2025 | Bronson David M. Director | Option exercise | 479 | $0 |
| Jun 3, 2025 | Farkas Charles Director | Option exercise | 479 | $0 |
| Jun 3, 2025 | Concannon Brian Director | Option exercise | 479 | $0 |
| Jun 3, 2025 | Schwarzentraub Barbara J Director | Option exercise | 479 | $0 |
| May 29, 2025 | Farkas Charles Director | Tax withheld | 966 | $55.7K |
| May 29, 2025 | Farkas Charles Director | Option exercise | 1,000 | $55.7K |
| May 20, 2025 | Workman John L Director | Option exercise | 479 | $28.7K |
| May 5, 2025 | Farkas Charles Director | Sale | 4,000 | $227.8K |
| Mar 31, 2025 | Garner Todd W Executive Vice President & CFO | Award | 371 | $21.3K |
| Mar 14, 2025 | SHAGORY PETER K EVP, STRAT & CORP DEVT | Tax withheld | 4,316 | $253.9K |
| Mar 14, 2025 | SHAGORY PETER K EVP, STRAT & CORP DEVT | Option exercise | 4,500 | $249.4K |
| Mar 7, 2025 | Lalomia Brent Vice President QA and RA | Tax withheld | 26 | $1.6K |
| Mar 7, 2025 | Lalomia Brent Vice President QA and RA | Option exercise | 75 | $0 |
| Feb 11, 2025 | Glaze Richard Chief Information Officer | Sale | 257 | $16.8K |
| Nov 20, 2024 | Glaze Richard Chief Information Officer | Option exercise | 375 | $0 |
| Nov 20, 2024 | Glaze Richard Chief Information Officer | Tax withheld | 118 | $8.3K |
| Nov 7, 2024 | Hartman Curt R President and CEO | Tax withheld | 24,303 | $1.82M |
| Nov 7, 2024 | Hartman Curt R President and CEO | Option exercise | 30,000 | $1.54M |
| Sep 5, 2024 | Farkas Charles Director | Tax withheld | 534 | $39.7K |
| Sep 5, 2024 | Farkas Charles Director | Option exercise | 1,000 | $39.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for CONMED Corp
Free account. Everything above stays public.
Write why you follow CONMED Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading